回盛生物（300871）公告，2024年营业收入12亿元，同比增长17.71%。归属于上市公司股东的净亏损 2015.56万元，去年同期净利润1678.08万元，由盈转亏。公司经本次董事会审议通过的利润分配预案 为：以2024年12月31日总股本1.66亿股剔除存放于回购专用证券账户75.36万股后的总股本1.65亿股为基 数，向全体股东每10股派发现金红利1.3元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股 转增0股。 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company's Q1 2025 performance showed strong growth, with operating revenue reaching 822 million yuan, a year-on-year increase of 20.00%, and net profit attributable to shareholders of 116 million yuan, up 28.45% year-on-year [4][6] - The company is actively building a pet ecosystem, enhancing its second growth curve through a strategic restructuring of its industrial chain [6] - The company has achieved a gross margin of 41.23% and a net profit margin of 14.62% in Q1 2025, indicating improved profitability [6] Summary by Sections Financial Performance - In Q1 2025, the company reported operating revenue of 822 million yuan, a 20.00% increase year-on-year, and a net profit of 116 million yuan, up 28.45% year-on-year [4][6] - The gross margin improved to 41.23%, an increase of 0.47 percentage points year-on-year, while the net profit margin rose to 14.62%, up 0.13 percentage points year-on-year [6] Business Strategy - The company is implementing a "Three-Rui Synergy" strategy to reconstruct its industrial chain, focusing on deep collaboration among its three core segments: RuiPu Bio, RuiPai Pet Hospital, and ZhongRui Supply Chain [6] - The pet segment achieved sales revenue of 689 million yuan in 2024, accounting for 22.47% of total revenue, an increase of 4.35 percentage points year-on-year [6] Future Outlook - Revenue forecasts for 2025-2027 have been adjusted to 3.658 billion, 4.203 billion, and 4.709 billion yuan, representing year-on-year growth rates of 19.14%, 14.92%, and 12.04% respectively [6][7] - Net profit forecasts for the same period are 498 million, 561 million, and 637 million yuan, with year-on-year growth rates of 65.64%, 12.70%, and 13.49% respectively [6][7]

Financial Performance - In Q1 2025, the company achieved a revenue of 8.22 billion yuan, representing a year-on-year growth of 20% [3] - The net profit attributable to shareholders was 1.16 billion yuan, with a year-on-year increase of 28.45% [3] - The non-recurring net profit reached 9.35 million yuan, showing a growth of 19.65% year-on-year [3] Business Strategy - The company is focusing on international brand strategy, marking its transition from a regional to a global brand [3] - A 56% stake acquisition in Zhongrui Supply Chain was completed, enhancing collaboration across core business segments [3] - The company is implementing a share repurchase plan, with a total repurchase amount of 120 million yuan as of March 31, 2025 [3] Product Development - The high pathogenic avian influenza vaccine generated 87 million yuan in revenue, a 16% increase year-on-year, while the Marek's vaccine revenue reached 26 million yuan, up 59% [4] - The company plans to launch new products, including a cat oral dewormer and various mRNA vaccines for pets, to enrich its product matrix [4][5] Market Expansion - The company has nearly 100% coverage of its top 100 customers in the traditional livestock sector and aims to deepen strategic cooperation with major clients [6][7] - The international strategy includes a dual circulation approach for product and technology, focusing on overseas market expansion and enhancing service capabilities [7] Impact of Tariffs - Export business accounts for approximately 3% of total revenue, indicating minimal direct impact from US-China tariffs [7] - The company is monitoring tariff policy changes to adjust its business layout and product strategies accordingly [7]

Core Insights - The company reported a revenue of 2.371 billion yuan for 2024, a year-on-year increase of 9.04%, and a net profit attributable to shareholders of 100 million yuan, up 15.90% [1] - In Q1 2025, the company achieved a revenue of 625 million yuan, reflecting a growth of 20.35%, with a net profit of 51 million yuan, an increase of 13.23% [1] - The company aims to become a world-leading animal health enterprise, focusing on new product development in veterinary pharmaceuticals and vaccines [1] Revenue and Profit Growth - The company’s 2024 revenue reached 2.371 billion yuan, marking a 9.04% increase year-on-year, while the net profit was 100 million yuan, up 15.90% [1] - For Q1 2025, the revenue was 625 million yuan, a 20.35% increase, and the net profit was 51 million yuan, reflecting a 13.23% growth [1] Product Development and Market Expansion - The company is the largest global producer of veterinary chlortetracycline premix, with a production capacity of 55,000 tons per year [2] - A new project will add 60,000 tons per year of chlortetracycline capacity, significantly reducing production costs [2] - The company is expanding its product matrix with a 1,000 tons per year doxycycline project, enhancing its veterinary pharmaceutical offerings [2] Vaccine Business Growth - The company has 16 vaccine products on the market, including those for pigs, ruminants, and pets, establishing a diverse product system [3] - In 2024, the company issued nearly 40 million doses of its blue ear disease vaccine, maintaining a strong market position [3] - The company is accelerating its pet health business, having established a pet division in Shanghai and currently offering 8 products with 11 more in the application process [3] Strategic Focus on Synthetic Biology - The company is leveraging synthetic biology as a key area for growth, aligning with national development plans that prioritize this technology [4] - A strategic partnership with Shanghai Jiao Tong University aims to enhance innovation and talent development in synthetic biology [4] - The company plans to utilize synthetic biology for advancements in veterinary pharmaceuticals and vaccines, aiming for significant technological and production scale improvements over the next 5-10 years [4]

Core Viewpoint - The company, Jinhe Biological, reported a revenue increase of 9.04% year-on-year for 2024, reaching 2.371 billion yuan, and a net profit increase of 15.90%, amounting to 100 million yuan. The first quarter of 2025 showed a revenue growth of 20.35% to 625 million yuan and a net profit increase of 13.23% to 51 million yuan [1][2]. Group 1: Financial Performance - In 2024, the company achieved an operating income of 2.371 billion yuan, a 9.04% increase year-on-year [1]. - The net profit attributable to shareholders for 2024 was 100 million yuan, reflecting a 15.90% year-on-year growth [1]. - For Q1 2025, the company reported an operating income of 625 million yuan, up 20.35% year-on-year, and a net profit of 51 million yuan, which is a 13.23% increase [1]. Group 2: Product Development and Market Position - Jinhe Biological is the largest producer of veterinary premix antibiotics globally, with a production capacity of 55,000 tons per year for chlortetracycline [1]. - The company has expanded its product matrix, focusing on both veterinary pharmaceuticals and vaccines, establishing a dual-driven growth model [1]. - The company has received GMP certification for a new production line that will add 60,000 tons per year of chlortetracycline capacity, significantly reducing production costs [1]. Group 3: Vaccine Business and Innovation - The company has 16 vaccine products on the market, including those for pigs, ruminants, and pets, indicating a diverse product system [2]. - In 2024, the company issued nearly 40 million doses of its blue ear disease inactivated vaccine, maintaining a second-place position for two consecutive years [2]. - A strategic cooperation agreement was signed with Shanghai Jiao Tong University to enhance research and development capabilities, focusing on synthetic biology and innovative vaccine development [2][3]. Group 4: Future Outlook - The company aims to leverage its core chlortetracycline premix and develop a multi-category pharmaceutical product strategy [3]. - Jinhe Biological is targeting the veterinary vaccine market to become a leading player in the domestic industry, with a focus on developing vaccines for various diseases [3].

Investment Rating - The report maintains an "Increase" rating for the agricultural, forestry, animal husbandry, and fishery industry [4] Core Viewpoints - The overall allocation in the agricultural sector is currently low, below the standard allocation level, indicating potential investment opportunities in leading companies as costs decrease and performance improves [3][18] - The report highlights a significant reduction in heavy allocations in the breeding sector, while other segments show minor changes [10][13] Summary by Sections Heavy Allocation Analysis - As of Q1 2025, the heavy allocation in the agricultural sector is 0.92%, a decrease of 0.08 percentage points quarter-on-quarter and 0.74 percentage points year-on-year [10][11] - The breeding industry accounts for 0.45% of heavy allocations, down 0.06 percentage points from the previous quarter [13][14] Company-Specific Changes - Among the top 15 heavy allocation stocks, most companies have reduced their allocations, with only Zhongchong Co., Ltd. increasing by approximately 0.03 percentage points [2][14] - The top five stocks with increased allocations include Zhongchong Co., Ltd. (+7.03%) and Ruipu Bio (+1.24%), while the top five with decreased allocations include Quanyin High-Tech (-2.37%) and Lihua Co., Ltd. (-2.24%) [2][15][16] Investment Recommendations - For the breeding sector, focus on leading companies like Muyuan Foods, Wens Foodstuff Group, and Shennong Group, as well as companies related to yellow chickens like Lihua Co., Ltd. [3][18] - In the breeding support sector, attention should be given to leading companies such as Haida Group and Bangji Technology [3][18] - The planting sector shows strong profitability stability, with recommendations for companies like Suqian Agricultural Development and Beidahuang Group [3][18]

登录新浪财经APP 搜索【信披】查看更多考评等级 5、公司将依据相关规定，及时做好信息披露工作，并在定期报告中披露报告期内使用闲置资金进行现 金管理的具体情况。 公司本次使用部分闲置自有资金进行现金管理，仅投资于安全性高、流动性好的短期保本或稳健型理财 产品，投资风险可控；但金融市场受宏观经济、市场波动的影响，不排除投资收益具有一定的不可预期 性。敬请广大投资者谨慎决策，注意防范投资风险。 五、决策程序的履行情况 公司于2025年4月24日召开第五届董事会第十八次会议、第五届监事会第十二次会议，分别审议通过了 《关于使用部分闲置自有资金进行现金管理的议案》；同意自股东大会审议通过之日起12个月内，在保 证正常经营所需流动资金的情况下，使用不超过人民币6.5亿元暂时闲置自有资金进行现金管理；在上 述额度内，该类资金可以单笔或分笔进行单次或累计滚动不超过一年期的现金管理，并授权由公司法定 代表人或其授权人员行使投资决策职责和具体实施。 该议案尚需提交股东大会审议通过。 特此公告 三、对公司的影响 1、公司本次使用部分闲置自有资金进行现金管理，是在确保公司日常经营和资金安全的前提下实施 的，不影响日常经营资金的正常 ...

Investment Rating - The report maintains a "Recommended" investment rating for the industry, suggesting a potential upside of over 15% relative to benchmark indices [4]. Core Insights - The swine industry shows stable breeding profits, with a focus on capacity reduction logic. The average price of external three yuan pigs was 15.0 CNY/kg, up 2.1% week-on-week, while the average weight of pigs sold was 128.6 kg, down 0.2% [19][20]. - The beef industry is at an inflection point, with strong price performance continuing. The average price of calves was 28.2 CNY/kg, up 2.1%, and the average price of fattened cattle was 25.8 CNY/kg, up 0.7% [23][30]. - The white chicken market is affected by ongoing avian influenza, with significant impacts on breeding stock and prices. The average price of white feather broiler chicks was 2.8 CNY/chick, up 9.5% [31][34]. - The animal health sector is seeing a recovery in demand as breeding supply stabilizes, with a notable increase in the issuance of vaccines [48][49]. Summary by Sections Swine Industry - The average price of external three yuan pigs was 15.0 CNY/kg, reflecting a week-on-week increase of 2.1%. The average weight of pigs sold was 128.6 kg, down 0.2%. The price of 15 kg external three yuan piglets was 668 CNY/head, with a slight decrease of 0.05% [19][21]. - Supply pressure remains stable, with normal sales rhythms from large producers and limited sales from smallholders. The demand side shows increased activity from secondary breeding, but overall consumption remains weak [20][21]. - The report recommends companies such as Muyuan Foods, Wens Foodstuff Group, and New Hope Liuhe for investment [20]. Beef Industry - The beef breeding industry is entering a capacity release phase, with the earliest signs of a price bottom forming. The report anticipates a potential recovery in the industry by late 2025 or early 2026 [23][30]. - The average wholesale price of beef was 61.4 CNY/kg, reflecting a slight increase of 0.2% [29][30]. - Recommended companies include Fucheng Co. and Guangming Meat Industry, focusing on integrated breeding and sales [23]. Poultry Industry - The average price of white feather broiler eggs was 1.6 CNY/egg, up 2.0%, while the average price of white feather broilers was 3.7 CNY/kg, up 2.2% [31][34]. - The report highlights the impact of avian influenza on breeding imports, particularly from the U.S. and New Zealand, which has been suspended for over three months [31][32]. - Recommended companies include Yisheng Livestock and He Feng Food [31]. Animal Health Sector - The demand for animal health products is expected to recover as breeding supply stabilizes. The issuance of vaccines has shown significant increases, particularly for swine diseases [48][49]. - The report recommends companies like Kexin Biological and Zhongmu Biotechnology, which are positioned to benefit from the recovery in the animal health market [49].

海利生物（603718）公告，2024年营业收入2.71亿元，同比增长12.59%。归属于上市公司股东的净利润 1.71亿元，同比增长172.28%。基本每股收益0.27元／股，同比增长170.00%。向全体股东每10股派发现 金红利0.784元(含税)。 ...

Investment Rating - The report rates the agricultural, forestry, animal husbandry, and fishery industry as "Overweight" [2][8] Core Viewpoints - The agricultural sector is expected to see a significant recovery in Q1 2025, with a projected net profit of 99.30 billion yuan, marking a year-on-year increase of 705% [4][5] - Key sub-sectors expected to show strong growth include seed and planting (+320%), pig farming (+278%), and chicken farming (+117%) [3][4] - The report highlights the performance of specific companies, with notable profit increases for Muyuansheng (289%), Wen's (246%), and Shennong Group (6550%) [3][6] Summary by Relevant Sections Pig Farming - In Q1 2025, despite a slight decline in pig prices, the cost optimization has led to profitability, with an average profit of 85.89 yuan per head [3][4] - The average price of pigs was 15.06 yuan/kg, down 9.43% from the previous quarter [3] - Major pig farming companies are expected to report a combined net profit of 66.70 billion yuan, a significant turnaround from losses [3][4] Chicken Farming - The white feather chicken sector is facing price declines across the supply chain, with significant drops in chick and meat prices [3][4] - The average price for white feather chicken chicks was 2.36 yuan each, down 29.2% year-on-year [3] - Despite challenges, companies like Shennong Development are expected to achieve profitability due to cost management [3][4] Pet Food - The pet food sector is projected to grow rapidly, driven by both domestic and international markets [3][4] - Exports of pet food increased by 9.1% in early 2025, with domestic brands launching new products [3][4] - Companies like Guibao Pet and Zhongchong are expected to see net profit increases of 21% and 42%, respectively [3][4] Animal Health - The increase in livestock numbers is expected to boost sales of veterinary products, with a projected recovery in revenue and net profit for listed companies [3][4] - The number of vaccine approvals increased by 23% year-on-year, indicating a recovery in demand [3][4] Investment Analysis - The report suggests focusing on investment opportunities across various agricultural sub-sectors, particularly in light of favorable tariff policies and the push for self-sufficiency [3][4] - Recommended companies for investment include Muyuansheng, Wen's, Haida Group, Guibao Pet, Shennong Development, and Longping High-Tech [3][4][9]